top of page

Data Engineer
Unblock Critical Data Pipelines

From long-running SQL and ETL jobs to new AI projects, make innovation the rule, not the exception, with Speedata's APU

PRIORITIZE KEY ANALYTICS PROJECTS THAT WERE ONCE IMPOSSIBLE, WITH NO WAIT OR RESOURCE CONSTRAINT

Driving business impact from critical ETL and data prep jobs and pre-processing for AI is a priority your infrastructure should be specifically designed to enable, not dependent on central IT's budget decisions from three years ago. While software has evolved to support the vision, Speedata’s APU is the only processor custom-built to drive the analytics use cases that deliver the most value from all your data.

Even when the entire data team agrees on the same objectives and projects, too often the infrastructure a data engineer needs to get started simply isn't available. With Speedata's APU, you can start and scale business-critical workloads without risk or cost.

KICK OFF ESSENTIAL PROJECTS ON YOUR OWN TIMELINE

CONSTANTLY REFRESH AND EXPAND YOUR DATA

Improving data quality — including both recency and scope — is one of the biggest demands on data engineers. But legacy systems and their costs encumber any improvements. Only an APU, a processor built for analytics' native speed and scale, can enable the most and best data to feed all your pipelines and workloads. 

The performance and management needed to prevent missed SLAs on the SQL and ETL jobs data teams rely on is beyond the systems most data engineers have access to. Speedata's APU is custom-built to accelerate workloads for Spark, Presto, and other modern analytics platforms up to 100x CPUs and GPUs.

TURBO-CHARGE PROCESSING FOR EVERY LONG-RUNNING WORKLOAD

GSK Mark.png

“I saw firsthand how Speedata's APU is opening the door for breakthroughs... With the unprecedented performance of this accelerator, analyzing data for drug discovery can be done in minutes, not hours — with endless lifesaving implications. This is only the beginning of hardware acceleration use cases.”

Mark Ramsey

former-CDO, GlaxoSmithKline

bottom of page